In:
Anti-Cancer Agents in Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 23, No. 9 ( 2023-05), p. 1067-1073
Abstract:
Colorectal cancer (CRC) is the third most common cancer worldwide. Current treatments, including
surgery, radiotherapy, and chemotherapy, are limited by severe side effects and the development of resistance. Objective: Therefore, it is important to find additional therapies to combat the problem. Ginsenoside Rb1 is the main
active ingredient of ginseng, which is a well-known herb in traditional Chinese medicine. Ginsenoside is reported to play an important role in the prevention and treatment of cancer. Methods: We established Azoxymethane (AOM)/Dextran sodium sulfate (DSS) colon cancer model based on inflammation,
observed the beneficial effect of ginsenoside Rb1, and detected the changes in gut microbiota. Results: Our experimental results showed that ginsenoside Rb1 significantly reduced the levels of TNF-α, IL-6, IL-
17A, IL-33, IL-1β, and IL-22, increased the level of IL-10, and also changed the gut microbiota composition. These results suggested that ginsenoside Rb1 can be used to prevent inflammation-associated CRC development and may
provide an effective therapeutic strategy for CRC by relieving chronic inflammation and restoring the gut microenvironment in the AOM/DSS-induced model of colitis-associated colorectal cancer in mice. Conclusion: Ginsenoside Rb1 significantly attenuated AOM/DSS-induced colon carcinogenesis.
Type of Medium:
Online Resource
ISSN:
1871-5206
DOI:
10.2174/1871520623666230119092735
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023
SSG:
15,3
